advertisement
Abstract #52005 Published in IGR 14-4
Short-term effect of topical brinzolamide-timolol fixed combination on ocular surface of glaucoma patients
Firat PG; Samdanci E; Doganay S; Cavdar M; Sahin N; Gunduz AInternational Journal of Ophthalmology 2012; 5: 714-718
AIM: To evaluate the short-term effect of the fixed combination of brinzolamide-timolol on the ocular surface in glaucoma patients. METHODS: This is a prospective study of 23 eyes of 23 patients with newly diagnosed glaucoma. Schirmer I test, tear break-up time (BUT) measurement, conjunctival impression cytology and central corneal thickness (CCT) measurements were performed in one of the eyes of each patients before and 4 weeks after brinzolamide-timolol fixed combination therapy. All patients were asked to answer the OSDI questionnaire form about the ocular surface symptoms at baseline and at 1 week and 4 weeks follow-up visits. RESULTS: After brinzolamide-timolol fixed combination theraphy Schirmer I, BUT and CCT values decreased but the only statistically significant decrease was seen in BUT test (P=0.03). OSDI scores increased during the follow-up but this increase was not statistically significant (P=0.22, P=0.42 respectively). Impression cytology findings ranged from 0.78±0.42 to 0.95±0.36 according to the Nelson classification. There was no statistically significant difference between baseline and 4 weeks follow up in impression cytology grades (P=0.15). CONCLUSION: The results of our study indicate that short-term use of brinzolamide-timolol fixed combination theraphy does not have a profound effect on ocular surface except BUT values.
Department of Ophthalmology, Turgut Ozal Medical Center, Inonu University, Malatya, Turkey.
Full articleClassification:
11.13.2 Betablocker and carbon anhydrase inhibitor (Part of: 11 Medical treatment > 11.13 Combination therapy)
11.16 Vehicles, delivery systems, pharmacokinetics, formulation (Part of: 11 Medical treatment)
2.1 Conjunctiva (Part of: 2 Anatomical structures in glaucoma)
